AP2201A - Sustained-release tablet composition of pramipexole. - Google Patents

Sustained-release tablet composition of pramipexole.

Info

Publication number: AP2201A
Authority: AP; ARIPO
Prior art keywords: pramipexole; sustained; release tablet; tablet composition; composition
Prior art date: 2002-07-25

Application number

AP2005003205A

Other languages

English (en)

Other versions

AP2005003205A0 (en

Inventor

Gregory E Amidon

John M Heimlich

Ernest J Lee

Original Assignee

Pharmacia Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-25

Filing date

2003-07-25

Publication date

2011-01-24

2003-07-25 Application filed by Pharmacia Corp filed Critical Pharmacia Corp

2005-03-31 Publication of AP2005003205A0 publication Critical patent/AP2005003205A0/xx

2011-01-24 Application granted granted Critical

2011-01-24 Publication of AP2201A publication Critical patent/AP2201A/xx

Links

239000000203 mixture Substances 0.000 title 1
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical group C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 title 1
229960003089 pramipexole Drugs 0.000 title 1
239000007939 sustained release tablet Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)

AP2005003205A 2002-07-25 2003-07-25 Sustained-release tablet composition of pramipexole. AP2201A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US39844702P	2002-07-25	2002-07-25
US39842702P	2002-07-25	2002-07-25
US47951303P	2003-06-18	2003-06-18

Publications (2)

Publication Number	Publication Date
AP2005003205A0 AP2005003205A0 (en)	2005-03-31
AP2201A true AP2201A (en)	2011-01-24

Family

ID=31192087

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2005003205A AP2201A (en)	2002-07-25	2003-07-25	Sustained-release tablet composition of pramipexole.

Country Status (41)

Country	Link
US (2)	US20050226926A1 (is)
EP (2)	EP1531814B1 (is)
JP (1)	JP4700963B2 (is)
KR (1)	KR100712832B1 (is)
CN (1)	CN1313092C (is)
AP (1)	AP2201A (is)
AR (1)	AR040681A1 (is)
AT (1)	ATE406162T1 (is)
AU (1)	AU2003261241B2 (is)
BR (1)	BR0312960A (is)
CA (1)	CA2492854C (is)
CR (1)	CR7661A (is)
CU (1)	CU23440B7 (is)
CY (1)	CY1110408T1 (is)
DE (1)	DE60323235D1 (is)
DK (1)	DK1531814T3 (is)
EA (2)	EA009663B1 (is)
EC (1)	ECSP055568A (is)
ES (1)	ES2310673T3 (is)
GE (1)	GEP20074048B (is)
HK (1)	HK10777456A1 (is)
HR (1)	HRP20041235B1 (is)
IL (1)	IL166078A0 (is)
IS (1)	IS7623A (is)
MA (1)	MA27328A1 (is)
ME (1)	MEP52308A (is)
MX (1)	MXPA05001054A (is)
MY (1)	MY138846A (is)
NO (1)	NO334298B1 (is)
NZ (1)	NZ537790A (is)
OA (1)	OA13303A (is)
PA (1)	PA8578301A1 (is)
PE (1)	PE20040130A1 (is)
PL (1)	PL215587B1 (is)
PT (1)	PT1531814E (is)
RS (1)	RS51719B (is)
SI (1)	SI1531814T1 (is)
TW (1)	TWI347849B (is)
UY (1)	UY27912A1 (is)
WO (1)	WO2004010997A1 (is)
ZA (1)	ZA200500439B (is)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2351303T3 (es) *	2001-12-11	2011-02-02	University Of Virginia Patent Foundation	Utilización de pramipexol para el tratamiento de la esclerosis lateral amiotrófica.
US20060281797A1 (en) *	2001-12-11	2006-12-14	University Of Virginia Patent Foundation	Neurorestoration with R(+) Pramipexole
MY136318A (en) *	2002-07-25	2008-09-30	Pharmacia Corp	Sustained-release tablet composition
PE20040134A1 (es) *	2002-07-25	2004-03-06	Pharmacia Corp	Forma de dosificacion de una vez al dia de pramipexol
US20050226926A1 (en)	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
WO2005005484A1 (ja)	2003-07-11	2005-01-20	Asahi Kasei Chemicals Corporation	機能性澱粉粉末
NZ553561A (en) *	2004-08-13	2010-12-24	Boehringer Ingelheim Int	Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
NZ553645A (en) *	2004-08-13	2010-09-30	Boehringer Ingelheim Int	Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
BRPI0419032B8 (pt) *	2004-09-09	2021-05-25	Psicofarma S A De C V	composição farmacêutica de liberação prolongada de hidralazina
EP1731514A1 (en) *	2005-06-02	2006-12-13	Sandoz AG	Process for the preparation of Pramipexole
ES2334061T3 (es) *	2005-08-15	2010-03-04	University Of Virginia Patent Foundation	Neurorrestauracion con pramipexol r(+).
US20090041844A1 (en) *	2006-02-10	2009-02-12	Boehringer Ingelheim International Gmbh	Modified Release Formulation
US20090098202A1 (en) *	2006-02-10	2009-04-16	Boehringer Ingelheim International Gmbh	Extended Release Formulation
WO2007090882A2 (en) *	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Pharmaceutical extended release compositions comprising pramipexole
US8518926B2 (en)	2006-04-10	2013-08-27	Knopp Neurosciences, Inc.	Compositions and methods of using (R)-pramipexole
WO2007121188A2 (en) *	2006-04-10	2007-10-25	Knopp Neurosciences, Inc.	Compositions and methods of using r(+) pramipexole
PL2026803T3 (pl) *	2006-05-16	2012-05-31	Knopp Neurosciences Inc	Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
WO2008001204A2 (en) *	2006-06-29	2008-01-03	Antares Pharma Ipl Ag	Transdermal compositions of pramipexole having enhanced permeation properties
US8524695B2 (en) *	2006-12-14	2013-09-03	Knopp Neurosciences, Inc.	Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2137171A4 (en)	2007-03-14	2010-05-19	Knopp Neurosciences Inc	SYNTHESIS OF BENZOTHIAZOLE DIAMINES SUBSTITUTED AND PURIFIED FROM THE CHIRAL PERSPECTIVE
EP2150239A1 (en) *	2007-04-24	2010-02-10	Boehringer Ingelheim International GmbH	Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US20080299189A1 (en) *	2007-06-04	2008-12-04	Drugtech Corporation	Controlled release dopamine agonist compositions
CA2725482A1 (en) *	2008-06-09	2009-12-17	Supernus Pharmaceuticals, Inc.	Controlled release formulations of pramipexole
US20110190356A1 (en)	2008-08-19	2011-08-04	Knopp Neurosciences Inc.	Compositions and Methods of Using (R)- Pramipexole
AU2010262970A1 (en) *	2009-06-19	2012-01-12	Knopp Neurosciences, Inc.	Compositions and methods for treating amyotrophic lateral sclerosis
EP2448411A4 (en) *	2009-07-02	2012-11-28	Supernus Pharmaceuticals Inc	METHOD OF TREATING A NEUROLOGICAL DISORDER
WO2011037976A2 (en) *	2009-09-22	2011-03-31	Dr. Reddy's Laboratories Limited	Pramipexole pharmaceutical formulations
EP2525786A2 (en)	2010-01-18	2012-11-28	Synthon BV	Pramipexole extended release tablets
TR201001862A1 (tr)	2010-03-11	2011-10-21	Sanovel �La� San.Ve T�C.A.�.	Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
AU2011256928A1 (en)	2010-05-24	2012-12-20	Lupin Limited	Extended release formulation of pramipexole
KR101307334B1 (ko) *	2010-07-02	2013-09-12	주식회사 바이오파마티스	프라미펙솔 또는 이의 약학적으로 허용되는 염을 포함하는 안정성이 개선된 서방형 약학 조성물
WO2013034173A1 (en)	2011-09-06	2013-03-14	Synthon Bv	Pramipexole extended release tablets
US9512096B2 (en)	2011-12-22	2016-12-06	Knopp Biosciences, LLP	Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2732812A1 (de)	2012-11-15	2014-05-21	Aristo Pharma GmbH	Pramipexol-Retardtablettenformulierung
US9662313B2 (en)	2013-02-28	2017-05-30	Knopp Biosciences Llc	Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en)	2013-07-12	2016-10-18	Knopp Biosciences Llc	Compositions and methods for treating conditions related to increased eosinophils
HRP20251187T1 (hr)	2013-07-12	2025-11-21	Areteia Therapeutics, Inc.	Liječenje povišenih razina eozinofila i/ili bazofila
US9642840B2 (en)	2013-08-13	2017-05-09	Knopp Biosciences, Llc	Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
US9763918B2 (en)	2013-08-13	2017-09-19	Knopp Biosciences Llc	Compositions and methods for treating chronic urticaria
CN103520128B (zh)	2013-10-12	2018-08-21	石家庄杏林锐步医药科技股份有限公司	一种普拉克索的缓释片剂、制备方法及其用途
IL312486B2 (en)	2017-04-10	2025-05-01	Chase Therapeutics Corp	NK1 antagonist combination and method for treating synucleinopathies
EP3615024B1 (en)	2017-04-24	2026-02-18	Alto Neuroscience, Inc.	Compositions comprising pramipexole and a 5ht3 antagonist for use in treating depression
JP7158425B2 (ja)	2017-06-30	2022-10-21	チェイスセラピューティクスコーポレイション	Ｎｋ－１アンタゴニスト組成物およびうつ病の処置における使用法
CN109316466B (zh) *	2017-07-31	2022-04-05	深圳翰宇药业股份有限公司	一种盐酸普拉克索缓释制剂及其制备方法
WO2019036624A1 (en)	2017-08-17	2019-02-21	Gu Zi Qiang	MONOAMINE PAMOATE SALT TYPE ANTI-PARKINSON AGENTS, PROCESS FOR PREPARING AND USING SAME
CN113876729B (zh) *	2021-11-11	2023-05-30	南通联亚药业股份有限公司	一种盐酸普拉克索缓释片剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4731374A (en) *	1984-12-22	1988-03-15	Dr. Karl Thomae Gmbh	Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals
WO1999016442A2 (en) *	1997-09-30	1999-04-08	Pharmacia & Upjohn Company	Sustained release tablet formulation to treat parkinson disease
EP0933079A1 (en) *	1998-02-03	1999-08-04	Cerestar Holding Bv	Free-flowable, directly compressible starch as binder, disintegrant and filler for compression tablets and hard gelatine capsules
US6277875B1 (en) *	2000-07-17	2001-08-21	Andrew J. Holman	Use of dopamine D2/D3 receptor agonists to treat fibromyalgia

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US15735A (en) *		1856-09-16		Improvement in harvesters
US2887440A (en) *	1957-08-12	1959-05-19	Dow Chemical Co	Enteric coating
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (ja)	1975-07-24	1983-01-06	武田薬品工業株式会社	Ｌ− アスコルビンサンセイザイノセイゾウホウ
US4140755A (en)	1976-02-13	1979-02-20	Hoffmann-La Roche Inc.	Sustained release tablet formulations
CH649215A5 (de)	1981-04-29	1985-05-15	Hoffmann La Roche	Pharmazeutische praeparate.
SE8103843L (sv)	1981-06-18	1982-12-19	Astra Laekemedel Ab	Farmaceutisk mixtur
US4424235A (en)	1981-09-14	1984-01-03	Hoffmann-La Roche Inc.	Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
DE3447075A1 (de) *	1984-12-22	1986-07-03	Dr. Karl Thomae Gmbh, 7950 Biberach	Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US4738851A (en)	1985-09-27	1988-04-19	University Of Iowa Research Foundation, Inc.	Controlled release ophthalmic gel formulation
US4709712A (en)	1986-10-22	1987-12-01	Dermatalogical Products Of Texas	Polycarboxylic acid polymer gels as protective agents
GB8828020D0 (en)	1988-12-01	1989-01-05	Unilever Plc	Topical composition
US5026559A (en)	1989-04-03	1991-06-25	Kinaform Technology, Inc.	Sustained-release pharmaceutical preparation
US5133974A (en)	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US5273975A (en)	1989-06-09	1993-12-28	The Upjohn Company	Heterocyclic amines having central nervous system activity
ES2067744T3 (es)	1989-06-09	1995-04-01	Upjohn Co	Aminas heterociclicas con actividad sobre el sistema nervioso central.
GB9015822D0 (en)	1990-07-18	1990-09-05	Beecham Group Plc	Compositions
US5472712A (en) *	1991-12-24	1995-12-05	Euroceltique, S.A.	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5656296A (en) *	1992-04-29	1997-08-12	Warner-Lambert Company	Dual control sustained release drug delivery systems and methods for preparing same
US5431920A (en)	1993-09-21	1995-07-11	Merck Frosst, Canada, Inc.	Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5458887A (en) *	1994-03-02	1995-10-17	Andrx Pharmaceuticals, Inc.	Controlled release tablet formulation
WO1997004752A1 (en) *	1995-07-26	1997-02-13	Duramed Pharmaceuticals, Inc.	Pharmaceutical compositions of conjugated estrogens and methods for their use
ES2248908T7 (es)	1997-06-06	2014-11-24	Depomed, Inc.	Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
SK180499A3 (en) *	1997-07-01	2001-08-06	Pfizer	Sertraline salts and sustained-release dosage forms of sertraline
US5895663A (en)	1997-07-31	1999-04-20	L. Perrigo Company	Pseudoephedrine hydrochloride extended-release tablets
CA2211778A1 (en) *	1997-08-14	1999-02-14	Francois Carriere	Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
DE69819748T2 (de)	1997-09-12	2004-09-30	Columbia Laboratories (Bermuda) Ltd.	Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6248358B1 (en)	1998-08-25	2001-06-19	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets and methods of making and using the same
US6624200B2 (en)	1998-08-25	2003-09-23	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US7153845B2 (en)	1998-08-25	2006-12-26	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US6056977A (en) *	1997-10-15	2000-05-02	Edward Mendell Co., Inc.	Once-a-day controlled release sulfonylurea formulation
NZ505807A (en)	1998-03-11	2003-01-31	Smithkline Beecham Corp	Controlled release oral dosage form containing [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl)acetonitrile monohydrochloride; useful for the treatment or prophylaxis of dementia
GB9812426D0 (en)	1998-06-10	1998-08-05	Reckitt & Colmann Prod Ltd	Improvements in or relating to organic compositions
TW407058B (en)	1998-07-17	2000-10-01	Dev Center Biotechnology	Oral cisapride dosage forms with an extended duration
DE19906290A1 (de)	1999-02-15	2000-08-17	Falk Pharma Gmbh	Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
US7374779B2 (en)	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
HRP20010700B1 (hr)	1999-03-31	2011-01-31	Janssen Pharmaceutica N.V.	Prezelatinizirani skrob u formulaciji s kontroliranim otpustanjem
DE19927688A1 (de)	1999-06-17	2000-12-21	Gruenenthal Gmbh	Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
DE60035232T2 (de)	1999-07-01	2008-02-14	Pharmacia & Upjohn Co. Llc, Kalamazoo	(S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
WO2001010405A1 (en)	1999-08-04	2001-02-15	Ranbaxy Laboratories Limited	Hydrodynamically balanced oral drug delivery system
US6387403B1 (en)	1999-09-15	2002-05-14	Alza Corporation	Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
WO2001022820A1 (en)	1999-09-30	2001-04-05	The General Hospital Corporation	Use of pramipexole as a treatment for cocaine craving
US20030180352A1 (en) *	1999-11-23	2003-09-25	Patel Mahesh V.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN1434713A (zh) *	1999-12-22	2003-08-06	法马西亚公司	环加氧酶－2抑制剂的缓释制剂
CA2332691C (en)	2000-01-27	2007-11-27	The York Group, Inc.	Death care merchandising system
CN1660435A (zh)	2000-02-24	2005-08-31	法玛西雅厄普约翰美国公司	新的药物联合形式
ES2187249B1 (es)	2000-09-18	2004-09-16	Synthon Bv	Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
SE0004671D0 (sv)	2000-12-15	2000-12-15	Amarin Dev Ab	Pharmaceutical formulation
DE10138275A1 (de)	2001-08-10	2003-02-27	Boehringer Ingelheim Pharma	Verbindungen zur Beseitigung der Anhedonie
US20030133982A1 (en)	2001-12-20	2003-07-17	Heimlich John M.	Zero-order sustained release dosage forms and method of making same
US20050226926A1 (en)	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
MY136318A (en)	2002-07-25	2008-09-30	Pharmacia Corp	Sustained-release tablet composition
CA2488860A1 (en)	2002-07-25	2004-02-05	Pharmacia Corporation	Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former
PE20040134A1 (es)	2002-07-25	2004-03-06	Pharmacia Corp	Forma de dosificacion de una vez al dia de pramipexol
US20040132826A1 (en)	2002-10-25	2004-07-08	Collegium Pharmaceutical, Inc.	Modified release compositions of milnacipran
AU2003224467A1 (en)	2003-03-11	2004-09-30	Korea United Pharm, Inc.	Process for the preparing of hardcapsule formulation containing lansoprazole
WO2004087175A1 (en)	2003-04-04	2004-10-14	Pharmacia Corporation	Oral extended release compressed tablets of multiparticulates
US20050020589A1 (en)	2003-06-18	2005-01-27	Pfizer Inc.	Sustained-release tablet composition comprising a dopamine receptor agonist
NZ553645A (en)	2004-08-13	2010-09-30	Boehringer Ingelheim Int	Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
NZ553561A (en)	2004-08-13	2010-12-24	Boehringer Ingelheim Int	Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006046256A1 (en)	2004-10-27	2006-05-04	Alembic Limited	Extended release formulation of pramipexole dihydrochloride
US20070148238A1 (en)	2005-06-23	2007-06-28	Spherics, Inc.	Dosage forms for movement disorder treatment
WO2007002518A1 (en)	2005-06-23	2007-01-04	Spherics, Inc.	Delayed release or extended-delayed release dosage forms of pramipexole
ES2334061T3 (es)	2005-08-15	2010-03-04	University Of Virginia Patent Foundation	Neurorrestauracion con pramipexol r(+).
WO2007054976A2 (en)	2005-11-08	2007-05-18	Panacea Biotec Ltd.	Lipid based controlled release pharmaceutical composition
US20090098202A1 (en)	2006-02-10	2009-04-16	Boehringer Ingelheim International Gmbh	Extended Release Formulation
US20090041844A1 (en)	2006-02-10	2009-02-12	Boehringer Ingelheim International Gmbh	Modified Release Formulation
WO2007090882A2 (en)	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Pharmaceutical extended release compositions comprising pramipexole
EP1886665A1 (en)	2006-08-01	2008-02-13	Boehringer Ingelheim Pharma GmbH & Co. KG	Gastro retentive delivery system

2003
- 2003-07-23 US US10/626,166 patent/US20050226926A1/en not_active Abandoned
- 2003-07-24 PA PA20038578301A patent/PA8578301A1/es unknown
- 2003-07-24 AR AR20030102666A patent/AR040681A1/es unknown
- 2003-07-24 PE PE2003000734A patent/PE20040130A1/es not_active Application Discontinuation
- 2003-07-24 MY MYPI20032784A patent/MY138846A/en unknown
- 2003-07-25 GE GEAP8599A patent/GEP20074048B/en unknown
- 2003-07-25 KR KR1020057001392A patent/KR100712832B1/ko not_active Expired - Fee Related
- 2003-07-25 HR HRP20041235AA patent/HRP20041235B1/hr not_active IP Right Cessation
- 2003-07-25 AT AT03771807T patent/ATE406162T1/de active
- 2003-07-25 EP EP03771807A patent/EP1531814B1/en not_active Expired - Lifetime
- 2003-07-25 WO PCT/US2003/023205 patent/WO2004010997A1/en not_active Ceased
- 2003-07-25 AP AP2005003205A patent/AP2201A/xx active
- 2003-07-25 EA EA200500079A patent/EA009663B1/ru not_active IP Right Cessation
- 2003-07-25 PT PT03771807T patent/PT1531814E/pt unknown
- 2003-07-25 DK DK03771807T patent/DK1531814T3/da active
- 2003-07-25 OA OA1200500016A patent/OA13303A/en unknown
- 2003-07-25 EP EP08159203A patent/EP1987832A1/en not_active Withdrawn
- 2003-07-25 BR BR0312960-8A patent/BR0312960A/pt not_active IP Right Cessation
- 2003-07-25 SI SI200331350T patent/SI1531814T1/sl unknown
- 2003-07-25 PL PL375696A patent/PL215587B1/pl unknown
- 2003-07-25 CN CNB038178737A patent/CN1313092C/zh not_active Expired - Fee Related
- 2003-07-25 CA CA002492854A patent/CA2492854C/en not_active Expired - Fee Related
- 2003-07-25 JP JP2004524787A patent/JP4700963B2/ja not_active Expired - Fee Related
- 2003-07-25 AU AU2003261241A patent/AU2003261241B2/en not_active Ceased
- 2003-07-25 ES ES03771807T patent/ES2310673T3/es not_active Expired - Lifetime
- 2003-07-25 ME MEP-523/08A patent/MEP52308A/xx unknown
- 2003-07-25 MX MXPA05001054A patent/MXPA05001054A/es active IP Right Grant
- 2003-07-25 NZ NZ537790A patent/NZ537790A/en unknown
- 2003-07-25 TW TW092120406A patent/TWI347849B/zh not_active IP Right Cessation
- 2003-07-25 EA EA200702187A patent/EA200702187A1/ru unknown
- 2003-07-25 DE DE60323235T patent/DE60323235D1/de not_active Expired - Lifetime
- 2003-07-25 RS YU20050059A patent/RS51719B/sr unknown
- 2003-07-31 UY UY27912A patent/UY27912A1/es not_active Application Discontinuation
2004
- 2004-12-29 IS IS7623A patent/IS7623A/is unknown
- 2004-12-30 IL IL16607804A patent/IL166078A0/xx unknown
2005
- 2005-01-06 NO NO20050093A patent/NO334298B1/no not_active IP Right Cessation
- 2005-01-17 ZA ZA200500439A patent/ZA200500439B/xx unknown
- 2005-01-24 EC EC2005005568A patent/ECSP055568A/es unknown
- 2005-01-24 CR CR7661A patent/CR7661A/es unknown
- 2005-01-25 CU CU20050018A patent/CU23440B7/es not_active IP Right Cessation
- 2005-01-25 MA MA28066A patent/MA27328A1/fr unknown
- 2005-11-08 HK HK05109947A patent/HK10777456A1/xx unknown
2008
- 2008-10-13 CY CY20081101125T patent/CY1110408T1/el unknown
2010
- 2010-03-03 US US12/716,755 patent/US8399016B2/en not_active Expired - Fee Related

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4731374A (en) *	1984-12-22	1988-03-15	Dr. Karl Thomae Gmbh	Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals
WO1999016442A2 (en) *	1997-09-30	1999-04-08	Pharmacia & Upjohn Company	Sustained release tablet formulation to treat parkinson disease
EP0933079A1 (en) *	1998-02-03	1999-08-04	Cerestar Holding Bv	Free-flowable, directly compressible starch as binder, disintegrant and filler for compression tablets and hard gelatine capsules
US6277875B1 (en) *	2000-07-17	2001-08-21	Andrew J. Holman	Use of dopamine D2/D3 receptor agonists to treat fibromyalgia

Also Published As

Publication number	Publication date
JP4700963B2 (ja)	2011-06-15
EA200702187A1 (ru)	2008-06-30
MY138846A (en)	2009-07-31
HRP20041235B1 (hr)	2013-07-31
AU2003261241B2 (en)	2009-06-18
EP1987832A1 (en)	2008-11-05
CN1313092C (zh)	2007-05-02
RS51719B (sr)	2011-10-31
US8399016B2 (en)	2013-03-19
TWI347849B (en)	2011-09-01
PL375696A1 (en)	2005-12-12
UY27912A1 (es)	2004-02-27
BR0312960A (pt)	2005-06-14
ES2310673T3 (es)	2009-01-16
WO2004010997A1 (en)	2004-02-05
CN1671382A (zh)	2005-09-21
DK1531814T3 (da)	2008-10-13
PA8578301A1 (es)	2004-07-20
ZA200500439B (en)	2006-08-30
TW200418523A (en)	2004-10-01
CA2492854A1 (en)	2004-02-05
NZ537790A (en)	2005-10-28
ATE406162T1 (de)	2008-09-15
US20100316710A1 (en)	2010-12-16
DE60323235D1 (de)	2008-10-09
EA200500079A1 (ru)	2005-06-30
RS20050059A (sr)	2007-08-03
IS7623A (is)	2004-12-29
IL166078A0 (en)	2006-01-15
WO2004010997A8 (en)	2005-02-24
MXPA05001054A (es)	2005-04-08
GEP20074048B (en)	2007-02-26
OA13303A (en)	2007-04-13
PE20040130A1 (es)	2004-03-06
AU2003261241A1 (en)	2004-02-16
NO20050093L (no)	2005-02-24
NO334298B1 (no)	2014-01-27
PL215587B1 (pl)	2013-12-31
SI1531814T1 (sl)	2008-12-31
EP1531814B1 (en)	2008-08-27
CR7661A (es)	2005-06-08
AP2005003205A0 (en)	2005-03-31
MEP52308A (en)	2011-02-10
CY1110408T1 (el)	2015-04-29
KR20050062516A (ko)	2005-06-23
HRP20041235A2 (en)	2005-06-30
CA2492854C (en)	2009-10-20
EA009663B1 (ru)	2008-02-28
KR100712832B1 (ko)	2007-04-30
JP2005538106A (ja)	2005-12-15
CU23440B7 (es)	2009-10-16
PT1531814E (pt)	2008-10-29
EP1531814A1 (en)	2005-05-25
ECSP055568A (es)	2005-04-18
HK10777456A1 (en)	2007-11-30
AR040681A1 (es)	2005-04-13
US20050226926A1 (en)	2005-10-13
MA27328A1 (fr)	2005-05-02

Publication	Publication Date	Title
AP2201A (en)	2011-01-24	Sustained-release tablet composition of pramipexole.
IL166079A0 (en)	2006-01-15	Sustained-release tablet comprising reboxetine
AP2223A (en)	2011-03-24	Pramipexole once-daily dosage form.
GB0218625D0 (en)	2002-09-18	Pharmaceutical compounds
GB0215775D0 (en)	2002-08-14	Pharmaceutical compounds
IL166607A (en)	2014-07-31	Granule fungicide formulation
GB0221513D0 (en)	2002-10-23	Novel compounds and processes
AU2003241671A8 (en)	2003-12-31	Controlled-release drug composition
AU149625S (en)	2002-10-21	Ring
DE60209673D1 (de)	2006-05-04	Tablettenbeschichtungen
PL377377A1 (pl)	2006-02-06	Nowe związki aminobenzofenonu
IL163778A0 (en)	2005-12-18	Processes for the synthesis of chloroadenosine andmethylthioadenosine
PL356853A1 (en)	2004-05-17	Application of bacteriphages
PL379864A1 (pl)	2006-11-27	Tabletki bromowodorku citalopramu
AU148728S (en)	2002-08-05	Tablet
AU148729S (en)	2002-08-05	Tablet
AU148730S (en)	2002-08-05	Tablet
GB0219744D0 (en)	2002-10-02	Tablet compositions
ZA200408338B (en)	2005-11-02	Heterocyclic compounds.
SI1537210T1 (sl)	2006-08-31	Lazna oligonukleotidna inhibicija ekspresije CD40
GB2392981B (en)	2004-08-11	Barometer
EP1511485A4 (en)	2006-04-12	NOVEL USES OF I DL / I -TETRAHYDROPALMATIN
SI1509241T1 (sl)	2007-02-28	Nove uporabe cefaibolov
AU147738S (en)	2002-05-06	Ring
ZA200407363B (en)	2006-02-22	Novel compounds.